Gilteritinib Changes AML Landscape

The US Food and Drug Administration recently approved gilteritinib (Xospata), in addition to final trial data from the phase 3 ADMIRAL trial, making it the new standard of care for acute myeloid leukemia.

Source: CancerNetwork - August 23, 2019 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news